RecruitingPhase 2NCT07298824

Clinical Efficacy and Mechanism Exploration of MR-61 in Delaying the Progression of Myopia

Clinical Efficacy and Mechanism Exploration of MR-61 in Delaying the Progression of Myopia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

Sponsor

Second Affiliated Hospital of Nanchang University

Enrollment

164 participants

Start Date

Oct 1, 2025

Study Type

INTERVENTIONAL

Conditions

Myopia Progressing

Summary

To investigate whether probiotic MR-61 can assist in slowing down the progression rate of myopia (a prospective randomized controlled study).

Eligibility

Min Age: 3 YearsMax Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called Investigational Bifidobacterium Preparation MR-61 and Placebo for MR-61 for people with myopia progressing. The study is currently recruiting participants at 1 location. People eligible for this study include aged 3 Years to 18 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALInvestigational Bifidobacterium Preparation MR-61

Oral administration of the investigational probiotic powder MR-61. The primary component is Bifidobacterium. Dosage: one sachet, 2-3 times daily, for 3 months.

OTHERPlacebo for MR-61

Oral administration of a matched placebo powder. Dosage: one sachet, 2-3 times daily, for 3 months.

Locations(1)

Yifeng Yu

Nanchang, Jiangxi, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07298824